BLCO (Bausch & Lomb) PE Ratio without NRI: 46.10 (As of Jun. 29, 2026) — Near Median


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $16.32
GF Value $18.37
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Bausch & Lomb PE Ratio without NRI?

Bausch & Lomb BLCO +2.58% 77 PE Ratio without NRI is 46.10 as of Jun. 29, 2026, which is 0% below its 10-year median of 46.14. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.37 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 446 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 79.82% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-29), Bausch & Lomb's share price is $16.32. Bausch & Lomb's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Therefore, Bausch & Lomb's PE Ratio without NRI for today is 46.10.

During the past 8 years, Bausch & Lomb's highest PE Ratio without NRI was 694.17. The lowest was 25.87. And the median was 46.14.

Bausch & Lomb's EPS without NRI for the three months ended in Mar. 2026 was $0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35.

As of today (2026-06-29), Bausch & Lomb's share price is $16.32. Bausch & Lomb's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.62. Therefore, Bausch & Lomb's PE Ratio (TTM) for today is At Loss.

During the past years, Bausch & Lomb's highest PE Ratio (TTM) was 1785.00. The lowest was 0.00. And the median was 97.32.

Bausch & Lomb's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.62.

Bausch & Lomb's EPS (Basic) for the three months ended in Mar. 2026 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.62.


Bausch & Lomb  (NYSE:BLCO) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Bausch & Lomb PE Ratio without NRI Related Terms


Bausch & Lomb PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Bausch & Lomb's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch & Lomb PE Ratio without NRI Chart

Bausch & Lomb Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial N/A 447.66 At Loss 28.91 33.31

Bausch & Lomb Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss 33.31 45.32

BLCO vs ISRG, BDX, MDLN: PE Ratio without NRI Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bausch & Lomb PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's PE Ratio without NRI falls into.


BLCO
77GF Score
Bausch & Lomb Corp BLCO
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bausch & Lomb PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Bausch & Lomb's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=16.32/0.354
=46.1

Bausch & Lomb's Share Price of today is $16.32.
Bausch & Lomb's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 46.10 mean?
Bausch & Lomb (BLCO) has a PE Ratio without NRI of 46.10 as of Jun. 29, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Bausch & Lomb and its competitors. This is near median its historical median of 46.14. Over the past decade, Bausch & Lomb's PE Ratio without NRI has ranged from 25.87 to 694.17. According to the industry distribution chart, Bausch & Lomb ranks #356 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 79.8%.
Is Bausch & Lomb's PE Ratio without NRI too high?
Bausch & Lomb's current PE Ratio without NRI of 46.10 is near median its 10-year median of 46.14. Over the past 10 years, this metric has ranged from a low of 25.87 to a high of 694.17. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.18. Bausch & Lomb's value of 46.10 is 98.9% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #356 out of 446 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's PE Ratio without NRI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #356 out of 446 companies for PE Ratio without NRI. This places Bausch & Lomb in the lower half of its industry. The industry median PE Ratio without NRI is 23.18. Bausch & Lomb's value of 46.10 is 98.9% above this benchmark. Historically, Bausch & Lomb's own PE Ratio without NRI has ranged from 25.87 to 694.17 over the past decade. While the company's 10-year median is 46.14 vs. the industry median of 23.18, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.18, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current PE Ratio without NRI of 46.10 is 98.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Bausch & Lomb and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current PE Ratio without NRI is 46.10, which is near median its own 10-year median of 46.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Modestly Undervalued. The stock's GF Value™ is $18.37, compared to a current price of $16.32 — trading 11.2% below its estimated fair value. The current PE Ratio without NRI is 46.10, which is near median its 10-year median of 46.14 and 98.9% above the Medical Devices & Instruments industry median of 23.18. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current PE Ratio without NRI is 46.10 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $16.32 is trading 11.2% below its estimated GF Value™ of $18.37. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • PE Ratio without NRI: 46.10 (near median its 10-year median of 46.14)
  • GF Value™: $18.37 vs. price of $16.32 (11.2% below fair value)
  • GF Score™: 77/100 with 9 warning signs
  • Industry Position: 98.9% above the Medical Devices & Instruments median (#356 of 446)

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.32
Price
$18.37
GF Value